The 36-month beta value for COEP is also noteworthy at -0.90. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for COEP is 29.24M, and at present, short sellers hold a 0.84% of that float. The average trading volume of COEP on December 03, 2024 was 255.43K shares.
COEP) stock’s latest price update
Coeptis Therapeutics Holdings Inc (NASDAQ: COEP) has seen a decline in its stock price by -1.23 in relation to its previous close of 0.20. However, the company has experienced a 1.42% gain in its stock price over the last five trading sessions. prnewswire.com reported 2024-12-03 that The Acquisition of NexGenAI Affiliates Network Expands Company’s Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth WEXFORD, Pa. , Dec. 3, 2024 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce the execution of a Binding Letter of Intent for the acquisition of NexGenAI Affiliates Network, a platform developed by NexGenAI Solutions Group and its affiliates (“NexGenAI”) that offers AI-powered marketing software and robotic process automation (“RPA”) capabilities.
COEP’s Market Performance
Coeptis Therapeutics Holdings Inc (COEP) has seen a 1.42% rise in stock performance for the week, with a 1.16% gain in the past month and a 2.14% surge in the past quarter. The volatility ratio for the week is 6.88%, and the volatility levels for the past 30 days are at 8.88% for COEP. The simple moving average for the past 20 days is 0.75% for COEP’s stock, with a -28.11% simple moving average for the past 200 days.
COEP Trading at 3.24% from the 50-Day Moving Average
After a stumble in the market that brought COEP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.35% of loss for the given period.
Volatility was left at 8.88%, however, over the last 30 days, the volatility rate increased by 6.88%, as shares surge +0.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.42% upper at present.
During the last 5 trading sessions, COEP rose by +1.32%, which changed the moving average for the period of 200-days by -59.90% in comparison to the 20-day moving average, which settled at $0.1988. In addition, Coeptis Therapeutics Holdings Inc saw -74.45% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at COEP starting from Cogley Brian, who purchase 5,000 shares at the price of $0.67 back on Jan 10 ’24. After this action, Cogley Brian now owns 30,000 shares of Coeptis Therapeutics Holdings Inc, valued at $3,350 using the latest closing price.
DeSilva Tara, the Director of Coeptis Therapeutics Holdings Inc, purchase 2,266 shares at $0.58 during a trade that took place back on Jan 12 ’24, which means that DeSilva Tara is holding 32,266 shares at $1,305 based on the most recent closing price.
Stock Fundamentals for COEP
Current profitability levels for the company are sitting at:
- -7.5 for the present operating margin
- 0.21 for the gross margin
The net margin for Coeptis Therapeutics Holdings Inc stands at -7.74. The total capital return value is set at -2.04. Equity return is now at value -205.37, with -127.52 for asset returns.
Based on Coeptis Therapeutics Holdings Inc (COEP), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -4.05. The debt to equity ratio resting at 0.35. The interest coverage ratio of the stock is -33.98.
Currently, EBITDA for the company is -20.16 million with net debt to EBITDA at -0.06. When we switch over and look at the enterprise to sales, we see a ratio of 5.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.40.
Conclusion
In summary, Coeptis Therapeutics Holdings Inc (COEP) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
